About the Report
- The adoptive cell space is continuing to grow with a 19% average annual growth in initiation of trials between 2012 – 2021 and a 36% average annual growth in drugs entering the clinic between 2002 – 2021.
- A total of 10,902 milestones have been announced across the entire adoptive cell therapies space, highlighting the high volume of activity within the space.
- Following on from previous activity, H1 of 2022 has seen high investment in the space. Therefore, we can expect to see an increase in the number of novel cell types and proprietary technologies emerging and entering the clinic.
- We hope you found this review of H1 and the 2022 landscape analysis useful and insightful.
Find out more
Speak with our Team
Our dedicated team can help you with questions by showing you how this insight and data is collated on Beacon.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
